1
|
3,4-Dideoxy-3,3,4,4-tetrafluoro- and 4-OH epimeric 3-deoxy-3,3-difluoro-α-GalCer analogues: Synthesis and biological evaluation on human iNKT cells stimulation. Eur J Med Chem 2019; 178:195-213. [PMID: 31185411 DOI: 10.1016/j.ejmech.2019.05.069] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 05/23/2019] [Accepted: 05/24/2019] [Indexed: 02/07/2023]
Abstract
iNKT cells recognize CD1d/α-galactosylceramide (α-GalCer) complexes via their invariant TCR receptor and stimulate the immune response. Many α-GalCer analogues have been investigated to interrogate this interaction. Following our previous work related to the modification of the hydrogen bond network between α-GalCer and CD1d, we have now focused our attention on the synthesis of 3-deoxy-3,3-difluoro- and 3,4-dideoxy-3,3,4,4-tetrafluoro-α-GalCer analogues, and studied their ability to stimulate human iNKT cells. In each case, deoxygenation at the indicated positions was accompanied by difluoro introduction in order to evaluate the resulting electronic effect on the stability of the ternary CD1d/Galcer/TCR complex which has been rationalized by modeling study. With deoxy-difluorination at the 3-position, the two epimeric 4-OH analogues were investigated to establish their capacity to compensate for the lack of the hydrogen bond donating group at the 3-position. The 3,4-dideoxytetrafluoro analogue was of interest to highlight the amide NH-bond hydrogen bond properties.
Collapse
|
2
|
Chemistry and Biology of Bioactive Glycolipids of Marine Origin. Mar Drugs 2018; 16:md16090294. [PMID: 30135377 PMCID: PMC6163716 DOI: 10.3390/md16090294] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 08/09/2018] [Accepted: 08/15/2018] [Indexed: 12/17/2022] Open
Abstract
Glycolipids represent a broad class of natural products structurally featured by a glycosidic fragment linked to a lipidic molecule. Despite the large structural variety of these glycoconjugates, they can be classified into three main groups, i.e., glycosphingolipids, glycoglycerolipids, and atypical glycolipids. In the particular case of glycolipids derived from marine sources, an impressive variety in their structural features and biological properties is observed, thus making them prime targets for chemical synthesis. In the present review, we explore the chemistry and biology of this class of compounds.
Collapse
|
3
|
Jukes J, Gileadi U, Ghadbane H, Yu T, Shepherd D, Cox LR, Besra GS, Cerundolo V. Non-glycosidic compounds can stimulate both human and mouse iNKT cells. Eur J Immunol 2016; 46:1224-34. [PMID: 26873393 PMCID: PMC4913735 DOI: 10.1002/eji.201546114] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 01/05/2016] [Accepted: 02/08/2016] [Indexed: 12/14/2022]
Abstract
Invariant natural killer T (iNKT) cells recognize CD1d/glycolipid complexes and upon activation with synthetic agonists display immunostimulatory properties. We have previously described that the non-glycosidic CD1d-binding lipid, threitolceramide (ThrCer) activates murine and human iNKT cells. Here, we show that incorporating the headgroup of ThrCer into a conformationally more restricted 6- or 7-membered ring results in significantly more potent non-glycosidic analogs. In particular, ThrCer 6 was found to promote strong anti-tumor responses and to induce a more prolonged stimulation of iNKT cells than does the canonical α-galactosylceramide (α-GalCer), achieving an enhanced T-cell response at lower concentrations compared with α-GalCer both in vitro, using human iNKT-cell lines and in vivo, using C57BL/6 mice. Collectively, these studies describe novel non-glycosidic ThrCer-based analogs that have improved potency in iNKT-cell activation compared with that of α-GalCer, and are clinically relevant iNKT-cell agonists.
Collapse
Affiliation(s)
- John‐Paul Jukes
- MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular MedicineUniversity of OxfordOxfordUK
| | - Uzi Gileadi
- MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular MedicineUniversity of OxfordOxfordUK
| | - Hemza Ghadbane
- MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular MedicineUniversity of OxfordOxfordUK
| | - Ting‐Fong Yu
- School of Biosciences, University of BirminghamEdgbastonBirminghamUK
- School of ChemistryUniversity of BirminghamEdgbastonBirminghamUK
| | - Dawn Shepherd
- MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular MedicineUniversity of OxfordOxfordUK
| | - Liam R. Cox
- School of ChemistryUniversity of BirminghamEdgbastonBirminghamUK
| | - Gurdyal S. Besra
- School of Biosciences, University of BirminghamEdgbastonBirminghamUK
| | - Vincenzo Cerundolo
- MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular MedicineUniversity of OxfordOxfordUK
| |
Collapse
|
4
|
Laurent X, Bertin B, Renault N, Farce A, Speca S, Milhomme O, Millet R, Desreumaux P, Hénon E, Chavatte P. Switching Invariant Natural Killer T (iNKT) Cell Response from Anticancerous to Anti-Inflammatory Effect: Molecular Bases. J Med Chem 2014; 57:5489-508. [DOI: 10.1021/jm4010863] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Xavier Laurent
- Faculté
de Médecine, Intestinal Biotech Development, Amphis J et K, Boulevard du Professeur Jules Leclerc, 59045 Lille Cedex, France
- Laboratoire
de Chimie Thérapeutique, EA 4481, Faculté des Sciences
Pharmaceutiques et Biologiques, Université Lille-Nord de France, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France
| | - Benjamin Bertin
- Faculté
de
Médecine, Université Lille-Nord de France, Amphis J
et K, INSERM U995, Boulevard du Professeur
Jules Leclerc, 59045 Lille Cedex, France
| | - Nicolas Renault
- Laboratoire
de Chimie Thérapeutique, EA 4481, Faculté des Sciences
Pharmaceutiques et Biologiques, Université Lille-Nord de France, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France
| | - Amaury Farce
- Laboratoire
de Chimie Thérapeutique, EA 4481, Faculté des Sciences
Pharmaceutiques et Biologiques, Université Lille-Nord de France, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France
| | - Silvia Speca
- Faculté
de
Médecine, Université Lille-Nord de France, Amphis J
et K, INSERM U995, Boulevard du Professeur
Jules Leclerc, 59045 Lille Cedex, France
| | - Ophélie Milhomme
- Institut
de Chimie Pharmaceutique Albert Lespagnol, EA 4481, Université Lille-Nord de France, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France
| | - Régis Millet
- Institut
de Chimie Pharmaceutique Albert Lespagnol, EA 4481, Université Lille-Nord de France, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France
| | - Pierre Desreumaux
- Faculté
de
Médecine, Université Lille-Nord de France, Amphis J
et K, INSERM U995, Boulevard du Professeur
Jules Leclerc, 59045 Lille Cedex, France
| | - Eric Hénon
- Université
de Reims Champagne-Ardenne, UFR des Sciences Exactes et Naturelles,
BSMA-ICMR, UMR CNRS 6229, Moulin de
la Housse, BP 1039, 51687 Reims Cedex 2, France
| | - Philippe Chavatte
- Laboratoire
de Chimie Thérapeutique, EA 4481, Faculté des Sciences
Pharmaceutiques et Biologiques, Université Lille-Nord de France, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France
- Institut
de Chimie Pharmaceutique Albert Lespagnol, EA 4481, Université Lille-Nord de France, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France
| |
Collapse
|
5
|
Jervis P, Polzella P, Wojno J, Jukes JP, Ghadbane H, Garcia
Diaz YR, Besra GS, Cerundolo V, Cox LR. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists. Bioconjug Chem 2013; 24:586-94. [PMID: 23458425 PMCID: PMC3630740 DOI: 10.1021/bc300556e] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Revised: 02/21/2013] [Indexed: 02/01/2023]
Abstract
Invariant natural killer T cells (iNKT cells) are restricted by CD1d molecules and activated upon CD1d-mediated presentation of glycolipids to T cell receptors (TCRs) located on the surface of the cell. Because the cytokine response profile is governed by the structure of the glycolipid, we sought a method for labeling various glycolipids to study their in vivo behavior. The prototypical CD1d agonist, α-galactosyl ceramide (α-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules. Analysis of crystal structures of the TCR-α-GalCer-CD1d ternary complex identified the α-methylene unit in the fatty acid side chain, and more specifically the pro-S hydrogen at this position, as a site for incorporating a label. We postulated that modifying the glycolipid in this way would exert a minimal impact on the TCR-glycolipid-CD1d ternary complex, allowing the labeled molecule to function as a good mimic for the CD1d agonist under investigation. To test this hypothesis, the synthesis of a biotinylated version of the CD1d agonist threitol ceramide (ThrCer) was targeted. Both diastereoisomers, epimeric at the label tethering site, were prepared, and functional experiments confirmed the importance of substituting the pro-S, and not the pro-R, hydrogen with the label for optimal activity. Significantly, functional experiments revealed that biotinylated ThrCer (S)-10 displayed behavior comparable to that of ThrCer 5 itself and also confirmed that the biotin residue is available for streptavidin and antibiotin antibody recognition. A second CD1d agonist, namely α-GalCer C20:2 4, was modified in a similar way, this time with a fluorescent label. The labeled α-GalCer C20:2 analogue (11) again displayed functional behavior comparable to that of its unlabeled substrate, supporting the notion that the α-methylene unit in the fatty acid amide chain should be a suitable site for attaching a label to a range of CD1d agonists. The flexibility of the synthetic strategy, and late-stage incorporation of the label, opens up the possibility of using this labeling approach to study the in vivo behavior of a wide range of CD1d agonists.
Collapse
MESH Headings
- Animals
- Antigens, CD1d/chemistry
- Antigens, CD1d/drug effects
- Antigens, CD1d/immunology
- Cells, Cultured
- Cytokines/analysis
- Cytokines/biosynthesis
- Cytokines/immunology
- Drug Design
- Galactosylceramides/chemistry
- Galactosylceramides/immunology
- Galactosylceramides/pharmacology
- Humans
- Mice
- Mice, Inbred C57BL
- Models, Molecular
- Molecular Conformation
- Natural Killer T-Cells/chemistry
- Natural Killer T-Cells/drug effects
- Natural Killer T-Cells/immunology
- Receptors, Antigen, T-Cell/chemistry
- Receptors, Antigen, T-Cell/immunology
Collapse
Affiliation(s)
- Peter
J. Jervis
- School of Chemistry, University
of Birmingham, Edgbaston, Birmingham B15
2TT, U.K
- School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15
2TT, U.K
| | - Paolo Polzella
- Medical Research
Council Human
Immunology Unit, Nuffield Department of Medicine, Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford OX3 9DS, U.K
| | - Justyna Wojno
- School of Chemistry, University
of Birmingham, Edgbaston, Birmingham B15
2TT, U.K
- School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15
2TT, U.K
| | - John-Paul Jukes
- Medical Research
Council Human
Immunology Unit, Nuffield Department of Medicine, Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford OX3 9DS, U.K
| | - Hemza Ghadbane
- Medical Research
Council Human
Immunology Unit, Nuffield Department of Medicine, Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford OX3 9DS, U.K
| | - Yoel R. Garcia
Diaz
- School of Chemistry, University
of Birmingham, Edgbaston, Birmingham B15
2TT, U.K
- School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15
2TT, U.K
| | - Gurdyal S. Besra
- School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15
2TT, U.K
| | - Vincenzo Cerundolo
- Medical Research
Council Human
Immunology Unit, Nuffield Department of Medicine, Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford OX3 9DS, U.K
| | - Liam R. Cox
- School of Chemistry, University
of Birmingham, Edgbaston, Birmingham B15
2TT, U.K
| |
Collapse
|
6
|
East JE, Kennedy AJ, Webb TJ. Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells. Med Res Rev 2012; 34:45-76. [PMID: 23239102 DOI: 10.1002/med.21276] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Natural killer T (NKT) cells serve as a bridge between the innate and adaptive immune systems, and manipulating their effector functions can have therapeutic significances in the treatment of autoimmunity, transplant biology, infectious disease, and cancer. NKT cells are a subset of T cells that express cell-surface markers characteristic of both natural killer cells and T cells. These unique immunologic cells have been demonstrated to serve as a link between the innate and adaptive immune systems through their potent cytokine production following the recognition of a range of lipid antigens, mediated through presentation of the major histocompatibility complex (MHC) class I like CD1d molecule, in addition to the NKT cell's cytotoxic capabilities upon activation. Although a number of glycolipid antigens have been shown to complex with CD1d molecules, most notably the marine sponge derived glycolipid alpha-galactosylceramide (α-GalCer), there has been debate as to the identity of the endogenous activating lipid presented to the T-cell receptor (TCR) via the CD1d molecule on antigen-presenting cells (APCs). This review aims to survey the use of pharmacological agents and subsequent structure-activity relationships (SAR) that have given insight into the binding interaction of glycolipids with both the CD1d molecules as well as the TCR and the subsequent immunologic response of NKT cells. These studies not only elucidate basic binding interactions but also pave the way for future pharmacological modulation of NKT cell responses.
Collapse
Affiliation(s)
- James E East
- Department of Microbiology and Immunology, The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201
| | | | | |
Collapse
|
7
|
Structure-activity relationship studies of novel glycosphingolipids that stimulate natural killer T-cells. Biosci Biotechnol Biochem 2012; 76:1055-67. [PMID: 22790924 DOI: 10.1271/bbb.120072] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
KRN7000, an anticancer drug candidate developed by Kirin Brewery Co. in 1995, is an α-galactosyl ceramide. It is a ligand making a complex with CD1d protein, and it stimulates invariant natural killer T (NKT) cells, which are one of the lineages of immunocytes. NKT cells activated by recognition of the CD1d/KRN7000 complex with its invariant T-cell receptor (TCR) can induce both protective and regulatory immune responses. To determine the recognition and activation mechanisms of NKT cells and to develop drug candidates more effective than KRN7000, a large number of analogs of KRN7000 have been synthesized. Some of them show potent bioactivities and have the potential of being utilized as therapeutic agents. In this review, structure-activity relationship studies of novel glycolipids which stimulate NKT cells efficiently are summarized.
Collapse
|
8
|
Wojno J, Jukes JP, Ghadbane H, Shepherd D, Besra GS, Cerundolo V, Cox LR. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production. ACS Chem Biol 2012; 7:847-55. [PMID: 22324848 PMCID: PMC3409616 DOI: 10.1021/cb2005017] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
Invariant natural killer T (iNKT) cells
are restricted
by the non-polymorphic MHC class I-like protein, CD1d, and activated
following presentation of lipid antigens bound to CD1d molecules.
The prototypical iNKT cell agonist is α-galactosyl
ceramide (α-GalCer). CD1d-mediated activation of iNKT cells by this molecule results in the rapid secretion of a range
of pro-inflammatory (Th1) and regulatory (Th2) cytokines. Polarization
of the cytokine response can be achieved by modifying the structure
of the glycolipid, which opens up the possibility of using CD1d agonists
as therapeutic agents for a range of diseases. Analysis of crystal
structures of the T-cell receptor−α-GalCer–CD1d
complex led us to postulate that amide isosteres of known CD1d agonists
should modulate the cytokine response profile upon iNKT-cell activation. To this end, we describe the synthesis and biological
activity of amide analogues of α-GalCer and its non-glycosidic
analogue threitol ceramide (ThrCer). All of the analogues were found
to stimulate murine and human iNKT cells by CD1d-mediated
presentation to varying degrees; however, the thioamide and carbamate
analogues of ThrCer were of particular interest in that they elicited
a strongly polarized cytokine response (more interferon-gamma (IFN-γ),
no interleukin-4 (IL-4)) in mice. While the ThrCer-carbamate analogue
was shown to transactivate natural killer (NK) cells, a mechanism
that has been used to account for the preferential production of IFN-γ
by other CD1d agonists, this pathway does not account for the polarized
cytokine response observed for the thioamide analogue.
Collapse
Affiliation(s)
| | - John-Paul Jukes
- Medical Research Council Human
Immunology Unit, Nuffield Department of Medicine, Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford OX3 9DS, U.K
| | - Hemza Ghadbane
- Medical Research Council Human
Immunology Unit, Nuffield Department of Medicine, Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford OX3 9DS, U.K
| | - Dawn Shepherd
- Medical Research Council Human
Immunology Unit, Nuffield Department of Medicine, Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford OX3 9DS, U.K
| | | | - Vincenzo Cerundolo
- Medical Research Council Human
Immunology Unit, Nuffield Department of Medicine, Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford OX3 9DS, U.K
| | | |
Collapse
|
9
|
Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α-galactosyl ceramide analogues. Carbohydr Res 2012; 356:152-62. [PMID: 22445102 PMCID: PMC3413882 DOI: 10.1016/j.carres.2012.02.034] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Accepted: 02/28/2012] [Indexed: 11/21/2022]
Abstract
A library of dimeric CD1d ligands, containing two α-galactosyl ceramide (α-GalCer) units linked by spacers of varying lengths has been synthesised. The key dimerisation reactions were carried out via copper-catalysed click reactions between a 6"-azido-6"-deoxy-α-galactosyl ceramide derivative and various diynes. Each α-GalCer dimer was tested for its ability to stimulate iNKT cells.
Collapse
|
10
|
Hunault J, Diswall M, Frison JC, Blot V, Rocher J, Marionneau-Lambot S, Oullier T, Douillard JY, Guillarme S, Saluzzo C, Dujardin G, Jacquemin D, Graton J, Le Questel JY, Evain M, Lebreton J, Dubreuil D, Le Pendu J, Pipelier M. 3-fluoro- and 3,3-difluoro-3,4-dideoxy-KRN7000 analogues as new potent immunostimulator agents: total synthesis and biological evaluation in human invariant natural killer T cells and mice. J Med Chem 2012; 55:1227-41. [PMID: 22243602 DOI: 10.1021/jm201368m] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We propose here the synthesis and biological evaluation of 3,4-dideoxy-GalCer derivatives. The absence of the 3- and 4-hydroxyls on the sphingoid base is combined with the introduction of mono or difluoro substituent at C3 (analogues 8 and 9, respectively) to evaluate their effect on the stability of the ternary CD1d/GalCer/TCR complex which strongly modulate the immune responses. Biological evaluations were performed in vitro on human cells and in vivo in mice and results discussed with support of modeling studies. The fluoro 3,4-dideoxy-GalCer analogues appears as partial agonists compared to KRN7000 for iNKT cell activation, inducing T(H)1 or T(H)2 biases that strongly depend of the mode of antigen presentation, including human vs mouse differences. We evidenced that if a sole fluorine atom is not able to balance the loss of the 3-OH, the presence of a difluorine group at C3 of the sphingosine can significantly restore human iNKT activation.
Collapse
Affiliation(s)
- Julie Hunault
- Université de Nantes, CNRS, Chimie et Interdisciplinarité: Synthèse, Analyse, Modélisation (CEISAM), UMR CNRS 6230, Faculté des Sciences et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
|
12
|
|
13
|
Banchet-Cadeddu A, Hénon E, Dauchez M, Renault JH, Monneaux F, Haudrechy A. The stimulating adventure of KRN 7000. Org Biomol Chem 2011; 9:3080-104. [DOI: 10.1039/c0ob00975j] [Citation(s) in RCA: 115] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
14
|
Padte NN, Li X, Tsuji M, Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol 2010; 140:142-51. [PMID: 21185784 DOI: 10.1016/j.clim.2010.11.009] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2010] [Revised: 11/08/2010] [Accepted: 11/16/2010] [Indexed: 01/12/2023]
Abstract
Natural killer T (NKT) cells are known to play a role against certain microbial infections, including malaria and HIV, two major global infectious diseases. Strategies that can harness and amplify the immunotherapeutic potential of NKT cells can serve as powerful tools in the fight against such diseases. 7DW8-5, a novel glycolipid, may be one such tool. The interaction of 7DW8-5 with CD1d molecules induces activation of NKT cells, thereby activating various immune-competent cells including dendritic cells (DCs) to provide a significant adjuvant effect for several vaccines. This review discusses the discovery and characterization of 7DW8-5 and the practical considerations of its preclinical and clinical development as a potential glycolipid adjuvant for candidate malaria and HIV vaccines.
Collapse
Affiliation(s)
- Neal N Padte
- Aaron Diamond AIDS Research Center, Affiliate of The Rockefeller University, New York, NY 10016, USA
| | | | | | | |
Collapse
|
15
|
Murphy N, Zhu X, Schmidt RR. α-Galactosylceramides and analogues – important immunomodulators for use as vaccine adjuvants. CARBOHYDRATE CHEMISTRY 2010. [DOI: 10.1039/9781849730891-00064] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Niamh Murphy
- UCD School of Chemistry and Chemical Biology, University College Dublin Belfield, Dublin 4 Ireland
| | - Xiangming Zhu
- UCD School of Chemistry and Chemical Biology, University College Dublin Belfield, Dublin 4 Ireland
| | - Richard R. Schmidt
- Fachbereich Chemie, Universität Konstanz Fach M 725 D-78457 Konstanz Germany
| |
Collapse
|
16
|
Tashiro T, Mori K. Fifteen Years since the Development of KRN7000 – Structure-Activity Relationship Studies on Novel Glycosphingolipids Which Stimulate Natural Killer T Cells. TRENDS GLYCOSCI GLYC 2010. [DOI: 10.4052/tigg.22.280] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Harrak Y, Barra CM, Bedia C, Delgado A, Castaño AR, Llebaria A. Aminocyclitol-substituted phytoceramides and their effects on iNKT cell stimulation. ChemMedChem 2009; 4:1608-13. [PMID: 19739197 DOI: 10.1002/cmdc.200900193] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Youssef Harrak
- Research Unit on BioActive Molecules (RUBAM), Departament de Química Biomèdica, Institut de Química Avançada de Catalunya (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona (Spain)
| | | | | | | | | | | |
Collapse
|
18
|
A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity. Semin Immunol 2009; 22:87-96. [PMID: 19962909 DOI: 10.1016/j.smim.2009.11.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2009] [Revised: 11/02/2009] [Accepted: 11/09/2009] [Indexed: 02/08/2023]
Abstract
NKT cells are known to play a role against certain microbial infections, including malaria and HIV, two major global infectious diseases. NKT cells exhibit either protective or pathogenic role against malaria. They are depleted by HIV infection and have a direct pathogenic role against many opportunistic infections common in end-stage AIDS. This review discusses the various features of the interaction between NKT cells and malaria parasites and HIV, and the potential to harness this interaction for therapeutic and vaccine strategies.
Collapse
|
19
|
Venkataswamy MM, Porcelli SA. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol 2009; 22:68-78. [PMID: 19945296 DOI: 10.1016/j.smim.2009.10.003] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2009] [Accepted: 10/26/2009] [Indexed: 12/17/2022]
Abstract
In spite of their relatively limited antigen receptor repertoire, CD1d-restricted NKT cells recognize a surprisingly diverse range of lipid and glycolipid antigens. Recent studies of natural and synthetic CD1d-presented antigens provide an increasingly detailed picture of how the specific structural features of these lipids and glycolipids influence their ability to be presented to NKT cells and stimulate their diverse immunologic functions. Particularly for synthetic analogues of alpha-galactosylceramides which have been the focus of intense recent investigation, it is becoming clear that the design of glycolipid antigens with the ability to precisely control the specific immunologic activities of NKT cells is likely to be feasible. The emerging details of the mechanisms underlying the structure-activity relationship of NKT cell antigens will assist greatly in the design and production of immunomodulatory agents for the precise manipulation of NKT cells and the many other components of the immune system that they influence.
Collapse
Affiliation(s)
- Manjunatha M Venkataswamy
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
| | | |
Collapse
|
20
|
Tashiro T, Nakagawa R, Hirokawa T, Inoue S, Watarai H, Taniguchi M, Mori K. RCAI-37, 56, 59, 60, 92, 101, and 102, cyclitol and carbasugar analogs of KRN7000: their synthesis and bioactivity for mouse lymphocytes to produce Th1-biased cytokines. Bioorg Med Chem 2009; 17:6360-73. [PMID: 19656685 DOI: 10.1016/j.bmc.2009.07.025] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2009] [Revised: 07/13/2009] [Accepted: 07/14/2009] [Indexed: 11/15/2022]
Abstract
Cyclitol [RCAI-37 (1), 59 (5), 92 (7), and 102 (2)] and carbasugar analogs [RCAI-56 (3), 60 (4), and 101 (6)] of KRN7000 were synthesized through coupling reactions of the corresponding cyclitol or carbasugar derivatives with a cyclic sulfamidate (9) as the key step. Bioassay showed RCAI-56 (3, carbagalactose analog of KRN7000), 59 (5, 1-deoxy-neo-inositol analog), and 92 (7, 1-O-methylated 5) to be remarkably potent stimulants of mouse lymphocytes to produce Th1-biased cytokines, such as interferon-gamma, in vivo. RCAI-60 (4, carbafucose analog) and RCAI-101 (6, 6-O-methylated 3) showed strong bioactivity, on the other hands, RCAI-37 (1, myo-inositol analog) and 102 (2, neo-inositol analog) induced little cytokine production.
Collapse
Affiliation(s)
- Takuya Tashiro
- Glycosphingolipid Synthesis Group, Laboratory for Immune Regulation, Research Center for Allergy and Immunology, RIKEN, Hirosawa 2-1, Wako-shi, Saitama 351-0198, Japan
| | | | | | | | | | | | | |
Collapse
|